Top Story
Value AssessmentMilliporeSigma, the life science division of Merck KGaA, has committed to a significant expansion in Asia-Pacific with a 300 million euro investment in a new bioprocessing facility in Daejeon, South Korea. This investment was announced less than a year after Merck KGaA’sKGaA’s initial plans for the [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
04/23/2024 04:45 PM ET
Zevra Therapeutics ZVRA date announcement
Zevra Therapeutics already had three catalyst announcements coming up, but they added another one today. On June 30, 2024, it will announce top-line results for their recent Phase 1 trial for KP1077. Our calculations show [...]
Read More
04/23/2024 04:45 PM ET
YS Biopharma Co. Ltd. YS date announcement
Now that the Phase 2/3 trial of PIKA Recombinant COVID-19 Vaccine is completed, YS Biopharma Co. Ltd. will announce their top-line results on June 30, 2024. Our predictive system gives the drug a 46% chance [...]
Read More
04/23/2024 04:45 PM ET
ABVC BioPharma TNXP date announcement
After specifying an announcement date for TNX-102 SL - (PREVAIL) trial results, Tonix Pharmaceuticals Holding now has three catalyst announcements planned. On June 30, 2024, Tonix Pharmaceuticals Holding will announce top-line results for their recent [...]
Read More
04/23/2024 04:45 PM ET
Abeona Therapeutics PPBT date announcement
Now that the Phase 1/2 trial of NT-219 is completed, Purple Biotech Ltd. will announce their top-line results on June 30, 2024. Our calculations show a 60.9% chance that the drug makes it to the [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
